Kinaxis Inc. (TSE:KXS – Get Free Report) Senior Officer Andrew William Robert Bell sold 100 shares of the business’s stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of C$184.74, for a total value of C$18,474.00. Following the completion of the sale, the insider now owns 831 shares of the company’s stock, valued at C$153,518.94. The trade was a 10.74 % decrease in their position.
Kinaxis Price Performance
Shares of TSE KXS opened at C$176.19 on Thursday. Kinaxis Inc. has a 1 year low of C$132.93 and a 1 year high of C$190.17. The stock has a market capitalization of C$4.98 billion, a P/E ratio of 176.19, a P/E/G ratio of 3.60 and a beta of 0.78. The company’s 50-day moving average is C$168.93 and its 200 day moving average is C$159.69. The company has a debt-to-equity ratio of 12.40, a current ratio of 1.90 and a quick ratio of 2.29.
Kinaxis (TSE:KXS – Get Free Report) last posted its earnings results on Wednesday, October 30th. The company reported C$0.47 earnings per share for the quarter, topping analysts’ consensus estimates of C$0.43 by C$0.04. Kinaxis had a return on equity of 4.87% and a net margin of 4.59%. The firm had revenue of C$165.79 million for the quarter, compared to the consensus estimate of C$170.56 million. On average, sell-side analysts expect that Kinaxis Inc. will post 4.2526231 earnings per share for the current year.
Analyst Upgrades and Downgrades
Check Out Our Latest Research Report on KXS
About Kinaxis
Kinaxis Inc provides cloud-based subscription software for supply chain operations in the United States, Europe, Asia, and Canada. It offers RapidResponse, a cloud-based platform, which provides advanced planning, sales and operation planning, supply and demand planning, inventory management, and command and control center services.
See Also
- Five stocks we like better than Kinaxis
- Do ETFs Pay Dividends? What You Need to Know
- Novo Nordisk: A New Boost for GLP-1 Sales on the Horizon
- Most Volatile Stocks, What Investors Need to Know
- Why Now Is the Ultimate Time to Invest in Oil Stocks
- Health Care Stocks Explained: Why You Might Want to Invest
- Q4’s Most Upgraded Stocks: Promising Buys for 2025
Receive News & Ratings for Kinaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kinaxis and related companies with MarketBeat.com's FREE daily email newsletter.